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Uromodulin is a monomeric glycoprotein excreted in large amounts in urine. Most of the assay
methods for quantifying uromodulin rely on the availability of antibodies to this glycoprotein. This
study reports a new bioassay for uromodulin without requiring the presence of antibodies. The bioassay
is based on the lectin affinity of the glycoprotein and the known interaction between uromodulin and the
tumor necrosis factor. The measuring range of the bioassay described in this paper is between 0.13 and
1.25 µg/ml, which makes it a potential method for clinical use.
Key Words: glycoprotein, methods, biological assay
Abbreviations used. THG, Tamm-Horsfall glycoprotein; TNF, tumor necrosis factor; Con A,
concanavalin A.

Introduction
Uromodulin, also known as Tamm-Horsfall glycoprotein (THG), derived from human pregnancy urine, is
a monomeric glycoprotein of 85 kDa1,2. It is produced in the thick ascending limb (TAL) and early distal
convoluted tubule (DCT) and is excreted in large amounts in urine. The immunosuppressive property
of Uromodulin is based on its glycosylation pattern that is different THG obtained from males and nonpregnant women3 . Although the exact physiological functions of uromodulin are yet to be clarified, a number
of researchers have reported its possible involvement in the regulation of ion transport, the urine-diluting
mechanism of nephrons, the pathogenesis of stone formation and in some forms of acute renal failure4 .
Uromodulin has also been reported to have a high binding affinity for tumor necrosis factor (TNF)5,6 .
Several assay methods have been developed to quantify uromodulin. Among these, radioimmunoassay
7

(RIA) and enzyme-linked immunosorbent assay (ELISA)8 are widely used. Although immunoassays are
selective and sensitive, these methods rely on the availability of specific polyclonal or monoclonal antibodies.
This study reports a sensitive and specific bioassay for uromodulin without the presence of antibodies. The
bioassay is based on the lectin affinity of the glycoprotein9 and the known interaction between uromodulin
and TNF5,6 . The results are monitored by using the mortality index of a mouse fibroblast L929 cell line.
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An Indirect Lectin Affinity Bioassay for Uromodulin..., Z. TOPCU

Experimental
1. Purification of Uromodulin: Uromodulin was isolated from the pooled 24 h urine of pregnant donors
by repeated salt precipitation in 0.58 M NaCl1,10). Samples of salt-precipitated material were further purified
by running over a cyanogen bromide-activated concanavalin A (Con A) sepharose (Sigma Chemical Co. St
Louis, MO) column with a total bed volume of 100 ml. Bound material was eluted with two bed volumes
of 250 mM methyl-mannoside in phosphate-buffered saline (PBS), pH 7.2. Following dialysis against three
changes of distilled water for 48 h at 4◦ C, the sample was lyophilized and resuspended in PBS containing
0.1% SDS and chromatographed on a 2.5 by 90 cm column packed with Bio Gel A 1.5 m (200-400 mesh size)
(Bio-Rad Inc. Richmond CA). The absorbance of fractions was monitored at 280 nm and the major elution
peak fractions were pooled.
2. Protein Determination: The protein concentration was determined as described11 .
3. Assay Protocol for Uromodulin: The bioassay was carried out in 96-well immunolon microtiter
plates (Dynatech Lab, Chantilly, VA). The wells were coated with 200 µl solution of Con A (5 µg/µl) in
0.1 M Na2 CO3 , pH 9.0, for 16 h at 4◦ C. The wells were then emptied and washed three times with PBS
containing 0.1% Tween-20, followed by the addition of 0.5% (w/v) BSA for 1 h to saturate the plastic
surface. The wells were washed twice with a solution containing 9 g/L NaCl, 0.2 g/L Tween-20, and 0.5 g/L
NaN3 . Different concentrations of isolated uromodulin, from 0.13 to 1.50 µg/ml, in 100 µl PBS were added
into wells in triplicate and incubated for 30 min with continuous shaking. Next, a constant amount of TNF
(100 µl of 0.1 µg/µl stock, a total of 3x103 units) in Dulbecco’s modified eagle medium (DMEM) was added
and incubated for another 30 min. All incubations were at room temperature. The amount of free TNF was
monitored using L929 cells. All reagents were of analytical grade.

Results and Discussion
1. Purification of Uromodulin The urine samples were collected from pregnant women as the immunosuppressive properties of uromodulin make the pregnant women rich in this glycoprotein1 . Figure 1 shows
the chromatographic elution profile during the purification of the salt-precipitated sample. The first peak,
containing blue dextran as indicator, was followed by the uromodulin peak, which comprised approximately
three-fourths of the applied material (Fig. 1, fractions between 40-80). The following fractions (Fig. 1,
fractions between 80-100) consisted of the peptides differing from uromodulin in molecular weight as well
as lectin affinity since they did not bind to Con A-coated immunolon plates. Analysis on a 7.5% (w/v)
SDS-PAGE showed that eluting the material from a Con A sepharose column eliminated heterogenous fractions of salt-precipitated sample, as a single band of 85 kDa protein was detected on the Coomassie brilliant
blue-stained gel (data not shown).
2. Lectin Affinity Assay: The quantitative method for uromodulin presented in this paper originated
from previous reports on the lectin affinity of glycoproteins9 , lectin-like interaction between uromodulin
and TNF5 , and the decreased cytolytic activity of TNF on monolayers of L929 cells in the presence of
uromodulin12. Binding specificity makes lectins highly useful in the purification and characterization of
glycoproteins. A lectin affinity bioassay reported by Electricwala employed immobilized lectins to quantify
tissue plasminogen activator using its chromogenic substrate9 . Among the lectins the author used, Con A
showed relatively higher binding affinity for the glycoprotein and binding was proportional to the amount
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of sample. Binding of uromodulin to TNF was first reported by Sherblom et al.5 . The authors reported
a lectin-like interaction of uromodulin with TNF via its mannose residues. On the other hand, Lambert
et al. have identified an inhibitory effect of uromodulin on the cytolytic activity of TNF for monolayers
of L929 cells when the cells were pre-treated with the glycoprotein and washed before the addition of the
cytokine12 . The rationale of the bioassay in this study is based on these three separate reports. When
a constant amount of TNF is added to Con A-coated, Uromodulin-added plates, the cytolytic activity of
TNF in L929 cells is limited to the fraction of free-TNF, unbound to uromodulin. Therefore, when a “Con
A/uromodulin/TNF sandwich” is applied to a L929 cell culture known to respond to TNF, the mortality of
the cells as a percentage can be converted into the amount of uromodulin. The optimal concentrations of

0.4

—

0.2

—

20

40

60

80

100

—

—

—

0.6

—

—

—

0.8

—

—

ABSORBANCE at 280 nm

100

—

sandwich components, Con A and TNF, were as described in the previous reports9,12 . The blocked fraction
of TNF did not exert its cytolytic activity and no interaction of TNF with either Con A or BSA was detected.

120

NUMBER of FRACTION

Figure 1. Chromatographic elution profile during the purification of the salt-precipitated sample of Uromodulin
from a Con A sepharose column. Fractions underlined were pooled separately and lyophilised. The flow rate and
volume of each fraction were 6 ml/h and 3.4 ml, respectively. See Experimental section for the details of purification.

Figure 2 shows a representative plot of dose response in the form of percent mortality (solid line)
and percent viability (broker line) of L929 cells versus uromodulin concentration (µg/ml). The results are
expressed as the average of the three parallel measurements. A proportional decrease in L929 cell mortality
is detected with the increased concentrations of uromodulin (Fig. 2, solid line). Dose-dependent change in
L929 survival also supports the previous reports on the individual interactions of the assay components5,9,12 .
The measuring range of the method is between 0.13 and 1.25 µg/ml of uromodulin. Therefore, this bioassay
has the potential to be used in clinical laboratory studies.
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Figure 2. A representative dose response curve in L929 cell line. Results are expressed as the average of three
parallel measurements of percent mortality (—-), and percent viability (- - -), versus uromodulin concentration
(µg/ml). Error bars are shown. See the text for the details of the experiment.

The other assay procedures, such as RIA7 and ELISA8 , involve the antibodies to estimate uromodulin. However, measurements using polyclonal antibodies may accommodate a population of molecules that
recognizes an antigenically dominant epitope on the glycoprotein. This may result in competition for the
same region of the molecule, which leads to a relatively low level of specific binding. The utilization of
site-specific or monoclonal antibodies may improve the sensitivity of measurements; however, uromodulin
exhibits a considerable polymorphism13. Thus, monitoring uromodulin with monoclonal antibodies might
lead to lower registrations of the actual amount. The bioassay presented in this study does not have a prerequisite for antibodies. On the other hand, methods based on the spectrophotometric protein determination of
salt-precipitated material are not useful, as urine samples of pregnant women contain a number of immunosuppressive glycopeptides14 . Some of these compounds may be the degradative products of uromodulin and
their presence can prevent the reliable estimation of the true magnitude.
Taken together, this is the first report on the use of lectins in a quantitative assay for Uromodulin
by employing TNF and a cell culture. However, it requires further improvements and simplifications to
be used in the clinical analysis of other biological fluids, i.e., serum and urine samples from men and nonpregnant women. The applicability of this method may show variations as the alteration of the sugar moiety
of uromodulin by pathological conditions15 can influence the affinity of the glycoprotein to the lectins.
Considering the measuring range of the method presented in this paper, a higher dilution may be required
as the concentration of Uromodulin reaches up to 4 mg/l in urine samples with different pathology8.
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